截止2020年09月21日22時(shí)02分EIDX（EIDX）最新價(jià)52.5600，漲跌額-0.1800，漲跌幅0.34%，昨收52.7400，今開52.3800，最高52.5600，最低50.6400，成交量8265手。

　　EIDX（EIDX）變動(dòng)日期2020年05月05日，變動(dòng)原因定期報(bào)告，已發(fā)行普通股3853.73萬，已發(fā)行優(yōu)先股--，公告日期2020年05月08日，已發(fā)行港股--，已發(fā)行國(guó)內(nèi)股--，已發(fā)行海外股3853.73萬，已發(fā)行其他股--。

　　EIDX（EIDX）2019年01月01日至2019年12月31日License revenue金額（USD）2669.10萬，比率100%。

　　EIDX（EIDX）主要指標(biāo)（幣種：美元）：截止2020年03月31日EIDX（EIDX）市盈率（TTM）-65.2110496980041，市凈率（MRQ）10.7070209421682，每股收益（TTM）-1.26957384008409，每股凈資產(chǎn)4.5372097675343，每股股息（USD）--，周息率--%，收入總額--，收入總額同比--%，歸母凈利潤(rùn)-2282.40萬，歸母凈利潤(rùn)同比-94.5282536435694%，毛利率--%，凈利率--%，總股本3853.73萬，總市值（USD）18.72億。

　　報(bào)告日期2020年03月31日，年結(jié)日12-31，幣種美元，EIDX（EIDX）收入--，收入增長(zhǎng)--%，毛利--，毛利增長(zhǎng)--%，歸母凈利潤(rùn)-2282.40萬，歸母凈利潤(rùn)增長(zhǎng)-94.53%，基本每股收益-0.6，稀釋每股收益-0.6，銷售毛利率--%，銷售凈利率--%。

　　報(bào)告日期2020年03月31日，年結(jié)日12-31，幣種美元，EIDX（EIDX）凈資產(chǎn)收益率-13.18%，總資產(chǎn)凈利率-11.07%。

　　公司介紹： Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. It seeks to treat this well-defined family of diseases by targeting them at their collective source by stabilizing TTR. TTR is a protein that occurs naturally in the form of a tetramer (a molecular structure consisting of four identical subunits, or monomers) and performs multiple beneficial roles, including the transport of essential hormones and vitamins. Over 25 years of research have shown that ATTR is uniformly driven by destabilization of the TTR tetramer, stemming from either specific gene mutations or aging. TTR destabilization drives an irreversible dissociation of the tetramer into monomers, which subsequently aggregate and deposit predominantly in the heart and peripheral nervous system, leading to organ damage, loss of organ function, and eventual death if left untreated. There are currently no therapies approved by the U.S. Food and Drug Administration, or FDA, for the treatment of ATTR. It is building upon its significant mechanistic understanding of ATTR to develop a potentially disease-modifying treatment for this family of diseases.

　　本站數(shù)據(jù)均為參考數(shù)據(jù)，不具備市場(chǎng)交易依據(jù)。